Regulation of insulin-like growth factor I (IGF-I) bioactivity in vivo: further characterization of an IGF-I-enhancing antibody.

Hill RA, Pell JM

Endocrinology1 Mar 1998Cited by 12 (Europe PMC)

PMID9492063DOI10.1210/endo.139.3.5804PepBankPUB-09492063

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dwarf rats, the duration of hypoglycaemia was more prolonged in LR3IGF-I-treated rats (P < 0.01); the abstract does not name the comparison group.
In plain wordsIn dwarf rats, the drop in blood sugar lasted longer in rats given LR3IGF-I, but the abstract does not say compared with which group.
Peptide
IGF-1 LR3
Outcome
IncreaseDuration of hypoglycaemia after LR3IGF-I
Study
ratn: not reported in source
dwarf rat
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneousAs given in this study (rat).
Source sentences
Summary
The duration of hypoglycemia was more prolonged in the LR3IGF-I-treated rats (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
3) The ability of the antibody to attenuate the acute hypoglycemic actions of IGF-I and LR3IGF-I was assessed by pretreating dwarf rats with either anti-IGF-I Ig or nonimmune Ig
Report a problemFND-0949206302

Studies that did not test the peptide alone4

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

02AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dwarf rats pretreated with nonimmune Ig, subcutaneous IGF-I or LR3IGF-I lowered plasma glucose by about 4 mM after 1 h (P < 0.001).
In plain wordsIn dwarf rats, IGF-I or LR3IGF-I injected under the skin lowered blood sugar by about 4 mM after one hour.
Peptide
IGF-1 LR3
Outcome
DecreasePlasma glucose 1 h after subcutaneous IGF-I or LR3IGF-I (nonimmune Ig pretreatment)
Study
ratn: not reported in source
dwarf rat
Outcome group
Glycemic control · Metabolic and weight
Measurements
plasma glucose decrease
≈ 4 mM
1 h after s.c. peptide, nonimmune Ig
Source sentences
Summary
1 h after s.c. administration of peptide, plasma glucose levels decreased by about 4 mM (P < 0.001) in rats pretreated with nonimmune Ig.
1 context sentence(design, population, supporting numbers)
Summary · context
3) The ability of the antibody to attenuate the acute hypoglycemic actions of IGF-I and LR3IGF-I was assessed by pretreating dwarf rats
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0949206301
03AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dwarf rats pretreated with anti-IGF-I Ig, neither IGF-I nor LR3IGF-I lowered circulating glucose, so the antibody protected against peptide-induced hypoglycaemia.
In plain wordsIn dwarf rats, an antibody to IGF-I stopped IGF-I and LR3IGF-I from lowering blood sugar.
Peptide
IGF-1 LR3
Outcome
No significant changeGlucose response to IGF-I and LR3IGF-I after anti-IGF-I Ig pretreatment
Study
ratn: not reported in source
dwarf rat
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Neither IGF-I or LR3IGF-I induced any decrease in circulating glucose concentrations in the rats pretreated with the anti-IGF-I Ig, suggesting that the antibody gave protection against inappropriate acute IGF-induced hypoglycemia.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0949206303
04AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dwarf mice, anti-IGF-I Ig did not change the anabolic action of LR3IGF-I, in contrast to its 3-fold potentiation of IGF-I.
In plain wordsIn dwarf mice, an antibody to IGF-I did not change weight gain caused by LR3IGF-I.
Peptide
IGF-1 LR3
Outcome
No significant changeWhole body weight gain with LR3IGF-I plus anti-IGF-I Ig
Study
mousen: not reported in source
dwarf mouse
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
but did not change the anabolic action of LR3IGF-I
1 context sentence(design, population, supporting numbers)
Summary · context
4) The potentiating effects of the anti-IGF-I Ig on the anabolic actions of IGF-I and LR3IGF-I were compared in dwarf mice.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0949206304
05AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Pharmacokinetics
In dwarf mice, anti-IGF-I Ig doubled circulating levels of both IGF-I and LR3IGF-I.
In plain wordsIn dwarf mice, an antibody to IGF-I doubled the blood levels of both IGF-I and LR3IGF-I.
Peptide
IGF-1 LR3
Outcome
IncreaseCirculating levels of IGF peptides with anti-IGF-I Ig
Study
mousen: not reported in source
dwarf mouse
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
despite its ability to double circulating levels of both IGF peptides
1 context sentence(design, population, supporting numbers)
Summary · context
4) The potentiating effects of the anti-IGF-I Ig on the anabolic actions of IGF-I and LR3IGF-I were compared in dwarf mice.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0949206305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.